Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ali Amini Harandi, Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT01696123
First received: September 21, 2012
Last updated: September 27, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)